This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canine Distemper Virus Therapeutic Antibody Development
Background of CDV
BioVenic delivers high-quality canine distemper virus (CDV) therapeutic antibody development services supported by our mature dedicated platform, state-of-the-art antibody discovery technologies and a comprehensive service portfolio. Canine Distemper Virus (CDV) is a highly contagious pathogen primarily targeting immune system cells, along with epithelial cells of the respiratory, gastrointestinal, and nervous systems. The widespread prevalence of CDV brings severe clinical symptoms and high mortality rates among susceptible canine populations, posing a persistent and significant threat to canine health. Reliable therapeutic antibodies are regarded as a promising strategy for prevention and clinical intervention against CDV infection.
Background of CDV
| Full Name | Canine Distemper Virus |
|---|---|
| Aliases | CDV |
| Target Profile | CDV, belonging to the Paramyxoviridae family and Morbillivirus genus, is a negative-sense single-stranded RNA virus. Its genome encodes several viral proteins, including the nucleocapsid (N), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin (H), and the large (L) protein. CDV infections typically affect the lymphatic system, respiratory system, gastrointestinal tract, and central nervous system, with symptoms including fever, cough, rhinitis, conjunctivitis, vomiting, diarrhea, and, in severe cases, neurological damage. |
MoA of CDV
The primary mechanism of CDV entry into host cells involves its surface glycoproteins H and F. These glycoproteins are key targets for CDV, responsible for the virus's attachment and membrane fusion with host cells. The H protein primarily recognizes and binds to receptors on the surface of host cells, such as SLAM and Nectin-4. Once the H protein binds to these receptors, the F protein facilitates the fusion of the viral envelope with the host cell membrane, enabling the virus to enter the cell.
Fig.1 Schematic diagram of CDV replication.1,2
Application in Veterinary Therapeutics
Canine distemper virus therapeutic antibodies have the ability to block the binding of the virus to host cell receptors, which in turn effectively prevents the virus from entering the host cell, thus reducing the replication and spread of the virus in the host. CDV infections usually result in severe respiratory and gastrointestinal symptoms, such as coughing, vomiting, and diarrhea, as well as neurological signs. The use of therapeutic antibodies can help alleviate these symptoms and improve the comfort and survival chances of infected canines.
Canine Distemper Virus Therapeutic Antibody Development Services
Given the significant health threat posed by CDV to canines, BioVenic has established the canine distemper virus therapeutic antibody development platform. Leveraging our extensive experience, we have established a diverse platform for discovering veterinary therapeutic antibodies, including hybridoma technology, single B cell technology, and phage display technology. Additionally, we offer antibody characterization and engineering services aimed at antibodies with high affinity and extended half-life. For canines, we specifically provide species-specific antibody development services, reducing the proportion of heterologous components in the antibody samples to decrease immunogenicity.
Please click the link below for more information about our canine CDV therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic utilizes a diverse array of antibody development technologies and optimizes the development process, providing comprehensive support for CDV therapeutic antibody development.
Our team provides targeted antigen solutions during the animal immunization phase, offering antigen expression and antigen potency testing services, as well as adjuvant addition to meet specific needs.
Throughout the entire process, we adhere to strict quality control and safety assessments, every step is ensured to meet standards, providing safe and effective treatment options for infected animals.
Frequently Asked Questions
What antibody discovery technologies do you apply for CDV therapeutic antibody development?
We adopt four mature antibody screening platforms for canine distemper virus antibody research: mouse hybridoma technology, single B cell isolation technology, phage display biopanning system and transgenic mouse hybridoma technology. After target antibody screening, we also conduct antibody modification such as CDR grafting, caninization and chimeric transformation to obtain low-immunogenic canine-specific antibodies.
Which CDV proteins serve as the core antigen targets for therapeutic antibody screening?
The H hemagglutinin protein and F fusion protein of canine distemper virus are our primary screening antigens. The H protein binds to host cell receptors SLAM and Nectin-4, while the F protein mediates viral membrane fusion. Antibodies targeting these two proteins can effectively block CDV attachment and invasion into canine cells.
What full one-stop services are covered in your CDV antibody development pipeline?
Our integrated workflow includes customized antigen expression and potency testing, matched adjuvant formulation and animal immunization, multi-platform antibody library construction and high-throughput screening, antibody gene amplification and vector construction, affinity optimization and canine-specific antibody engineering, plus full-process quality control and biosafety evaluation.
How do CDV therapeutic antibodies exert curative effects on infected dogs?
The therapeutic antibodies bind specifically to viral surface glycoproteins to block CDV's recognition and binding to canine cell receptors, inhibit viral membrane fusion and intracellular entry, reduce viral replication and systemic spread in the body, and relieve fever, respiratory, gastrointestinal and neurological clinical symptoms to raise the survival rate of sick canines.
What advantages does your caninized CDV antibody solution have over murine-derived raw antibodies?
Our team performs species-specific antibody transformation to minimize heterologous protein components in antibody molecules. This greatly lowers the risk of immune rejection in canine bodies, extends antibody half-life in vivo, and delivers more stable and long-lasting neutralizing efficacy for clinical treatment of canine distemper.
Partner with BioVenic
Immunotherapeutic interventions against CDV, such as the development of therapeutic antibodies, effectively control canine distemper by neutralizing the virus and preventing its invasion into host cells, thus reducing viral replication and spread. BioVenic offers a one-stop service for canine distemper therapeutic antibody development, committed to providing a convenient service experience. If you are considering developing CDV therapeutic antibodies, please contact us immediately, let's work together to advance animal health.
References
- Rendon-Marin, Santiago, et al. "Tropism and molecular pathogenesis of canine distemper virus." Virology journal 16 (2019): 1-15.
- Image retrieved from Figure 3 "Replication of the CDV cycle."Rendon-Marin, Santiago, et al., 2019, used under [CC BY 4.0], the image title was changed to "Schematic diagram of CDV replication."